B cell abnormalities and therapeutic strategies in systemic sclerosis

Area of Science:

• Immunology
• Rheumatology
• Cell Biology

Background:

• B cells are key players in humoral immunity, producing antibodies to neutralize pathogens.
• Beyond antibody production, B cells regulate immune responses through antigen presentation and cytokine secretion.
• Systemic sclerosis (SSc) involves autoimmunity and fibrosis, with abnormal B cell activity and autoantibodies linked to disease manifestations.

Purpose of the Study:

• To review current knowledge on B cell biology and its role in systemic sclerosis (SSc) pathogenesis.
• To discuss therapeutic strategies targeting B cells for SSc treatment.

Main Methods:

• Review of existing literature on B cell function in autoimmunity and SSc.
• Analysis of therapeutic approaches targeting B cell surface molecules and activation pathways.

Main Results:

• B cells exhibit chronic hyper-reactivity and produce autoantibodies associated with SSc phenotypes.
• Conventional treatments for SSc have limitations, leading to exploration of novel therapies.
• B cell-depleting therapies, such as rituximab, demonstrate potential for treating SSc.

Conclusions:

• B cells play a significant role in SSc pathogenesis beyond antibody production.
• Targeting B cell-specific surface molecules and pathways offers a promising therapeutic avenue for SSc.
• B cell-depleting therapy represents a potential advancement in managing SSc and related autoimmune diseases.